Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy.

Goding SR, Wilson KA, Rosinsky C, Antony PA.

J Immunol. 2018 May 1;200(9):3304-3311. doi: 10.4049/jimmunol.1701617. Epub 2018 Mar 30.

2.

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.

Joshi SS, Jiang S, Unni E, Goding SR, Fan T, Antony PA, Hornyak TJ.

PLoS One. 2018 Feb 26;13(2):e0191264. doi: 10.1371/journal.pone.0191264. eCollection 2018.

3.

RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis.

Rus V, Nguyen V, Tatomir A, Lees JR, Mekala AP, Boodhoo D, Tegla CA, Luzina IG, Antony PA, Cudrici CD, Badea TC, Rus HG.

J Immunol. 2017 May 15;198(10):3869-3877. doi: 10.4049/jimmunol.1602158. Epub 2017 Mar 29.

4.

A role for pre-mNK cells in tumor progression.

Rosinsky C, Antony PA.

J Immunother Cancer. 2016 Mar 15;4:16. doi: 10.1186/s40425-016-0120-6. eCollection 2016.

5.

Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

Wilson KA, Goding SR, Neely HR, Harris KM, Antony PA.

Oncoimmunology. 2015 Apr 1;4(8):e1019196. eCollection 2015 Aug.

6.

Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.

Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA.

Eur J Immunol. 2014 Jan;44(1):69-79. doi: 10.1002/eji.201343718. Epub 2013 Nov 21.

7.

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA.

J Immunol. 2013 May 1;190(9):4899-909. doi: 10.4049/jimmunol.1300271. Epub 2013 Mar 27.

8.

Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, Hu HM, Petrausch U, Restifo NP, Fox BA.

J Immunol. 2012 Jul 15;189(2):767-76. doi: 10.4049/jimmunol.1103822. Epub 2012 Jun 20.

9.

Th17 cells are long lived and retain a stem cell-like molecular signature.

Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.

Immunity. 2011 Dec 23;35(6):972-85. doi: 10.1016/j.immuni.2011.09.019. Epub 2011 Dec 15.

10.

GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.

Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT.

J Immunol. 2010 Sep 1;185(5):2828-35. doi: 10.4049/jimmunol.1000945. Epub 2010 Jul 28.

11.

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA.

J Exp Med. 2010 Mar 15;207(3):651-67. doi: 10.1084/jem.20091921. Epub 2010 Feb 15.

12.

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP.

J Exp Med. 2010 Mar 15;207(3):637-50. doi: 10.1084/jem.20091918. Epub 2010 Feb 15.

13.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.

Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.

14.

Toll-like receptors in tumor immunotherapy.

Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5280-9. Review.

15.

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP.

J Clin Invest. 2007 Aug;117(8):2197-204. Erratum in: J Clin Invest. 2007 Oct;117(10):3140.

16.
17.

CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP.

Blood. 2006 Dec 1;108(12):3818-23. Epub 2006 Aug 1.

18.

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.

Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Klebanoff CA, Tagaya Y, Restifo NP.

J Immunol. 2006 May 1;176(9):5255-66. Erratum in: J Immunol. 2006 Jun 15;176(12):7788. Heinrichs, Christian [corrected to Hinrichs, Christian S].

19.

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP.

J Exp Med. 2005 Oct 3;202(7):907-12.

20.

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP.

Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6. Epub 2005 Jun 24.

21.

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP.

J Immunol. 2005 Mar 1;174(5):2591-601.

22.

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Antony PA, Restifo NP.

J Immunother. 2005 Mar-Apr;28(2):120-8. Review.

23.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP.

Trends Immunol. 2005 Feb;26(2):111-7. Review. No abstract available. Erratum in: Trends Immunol. 2005 Jun;26(6):298.

24.

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.

Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP.

J Leukoc Biol. 2004 Aug;76(2):333-7. Epub 2004 May 20.

25.
26.

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74. Epub 2004 Feb 4.

27.

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.

J Exp Med. 2003 Aug 18;198(4):569-80.

28.

Interferon-gamma expression by intraepithelial lymphocytes results in a loss of epithelial barrier function in a mouse model of total parenteral nutrition.

Yang H, Kiristioglu I, Fan Y, Forbush B, Bishop DK, Antony PA, Zhou H, Teitelbaum DH.

Ann Surg. 2002 Aug;236(2):226-34.

29.

Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?

Antony PA, Restifo NP.

J Immunother. 2002 May-Jun;25(3):202-6.

30.

Assumptions of the tumor 'escape' hypothesis.

Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE.

Semin Cancer Biol. 2002 Feb;12(1):81-6. Review.

31.

The pattern of expression of CD147/neurothelin during human T-cell ontogeny as defined by the monoclonal antibody 8D6.

Kirsch AH, Diaz LA Jr, Bonish B, Antony PA, Fox DA.

Tissue Antigens. 1997 Aug;50(2):147-52.

Supplemental Content

Loading ...
Support Center